Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Azafaros Completes EUR 25 Million Series A Financing to Advance Rare ...
Azafaros – NNPDF
Azafaros secures 132 million euros in Series B financing | The Pharmaletter
Congratulations, again, Stefano Portolano, MD and entire AZAFAROS B.V ...
Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in ...
Azafaros - 2025 Funding Rounds & List of Investors - Tracxn
AZAFAROS B.V. on LinkedIn: #bioeurope #rarediseases #biotech # ...
Azafaros bags €132m for rare neuro-metabolic disorder drugs | pharmaphorum
Azafaros B.V. | BioPartner Leiden
AZAFAROS B.V. on LinkedIn: #nizubaglustat #collaboration #rarediseases ...
Azafaros - BIO International Convention 2026
Home | Azafaros B.V.
AZAFAROS B.V. on LinkedIn: #gm1 #gm2 #npc #world2024 #worldsymposia # ...
AZAFAROS B.V. - Naarden, Netherlands
Azafaros Switzerland AG – Swiss Biotech
Azafaros to present data from PRONTO study in patients with GM1 and GM2 ...
#porto | AZAFAROS B.V.
Azafaros Media Release | July 16, 2024
Azafaros Receives FDA’s IND Clearance and Fast Track Designation ...
AZAFAROS B.V. on LinkedIn: #managementteam #pharmaexecutives # ...
Azafaros Announces Key Scientific Oral and Poster Presentations on ...
Azafaros Strengthens Medical and Scientific Management Team Reflecting ...
Azafaros B.V. - BIO International Convention 2026
Azafaros Raises $150M To Target Rare Neuro-Metabolic Diseases - BioSpace
AZAFAROS B.V. | AZAFAROS B.V. | 22 comments
AZAFAROS B.V. on LinkedIn: #gm2 #npc #azafaros #rarediseases #rainbow
Azafaros Community Meeting (June 27, 2023) - YouTube
Azafaros Announces Initiation of two Global Phase 3 studies with ...
Dutch biotech Azafaros gets $146M for Phase 3 trials in three metabolic ...
AZAFAROS B.V. on LinkedIn: #worldsymposia #world2024 #gm1 #gm2 #npc # ...
About us | Azafaros B.V.
AZAFAROS B.V. on LinkedIn: #clinicaltrials #rarediseases #gm2 # ...
AZAFAROS B.V. on LinkedIn: #gm2 #gm1 #canavan #ntsaddoh23 # ...
AZAFAROS B.V. on LinkedIn: #rarediseases #niemannpickawareness #nnpdf # ...
Azafaros and Nizubaglustat Presentation - YouTube
A huge thank you to AZAFAROS B.V. for sponsoring our 9th European Tay ...
Azafaros Raises €146 Million to Propel Phase 3 Trials for Metabolic ...
Azafaros reports positive data from Phase II trial of nizubaglustat
AZAFAROS B.V. on LinkedIn: #ssiem2024 #gm1 #gm2 #npc #collaboration # ...
AZAFAROS B.V. | AZAFAROS B.V.
Azafaros Raises €132M to Propel Phase 3 Trials for Rare Disease ...
AZAFAROS B.V. on LinkedIn: #grids #raredisease #biotech #conferencing # ...
AZAFAROS B.V. on LinkedIn: #sleimpn #nizubaglustat #npc #gm1 #gm2 # ...
AZAFAROS B.V. on LinkedIn: #clinical #preclinical # ...
NTSAD GM2 Breakout | Azafaros - YouTube
AZAFAROS B.V. on LinkedIn: #pronto #rainbow #npc #azafaros #sleimpn2024 ...
Disease information | Azafaros B.V.
Forbion on LinkedIn: Azafaros Receives FDA’s IND Clearance and Fast ...
Azafaros Secures €132M in Oversubscribed Series B Financing to Advance ...
AZAFAROS B.V. on LinkedIn: #worldsymposia #world2024 #gm1 #research # ...
BGV Portfolio Company Azafaros announces Oversubscribed €132M Series B ...
AZAFAROS B.V. on LinkedIn: #gm1 #gm2 #npc #nizubaglustat #collaboration ...
AZAFAROS B.V. on LinkedIn: #odd #niemann #npc
Azafaros Highlights New Hope for Rare Lysosomal Diseases – Patient Worthy
Azafaros to develop new treatments for rare metabolic disorders
Today on International #RareDiseaseDay (28 February) the AZAFAROS B.V ...
Dutch-based Azafaros raises €132M
AZAFAROS B.V. on LinkedIn: #nnpdf #mayoclinic #nizubaglustat #nnpdf # ...
Azafaros bags €132m for rare neuro-metabolic disorder drugs - NEWS - 13 ...
Azafaros announces completion of Phase 2 RAINBOW study evaluating ...
Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III
Azafaros Highlights New Hope for Rare Lysosomal Diseases - Patient ...
Azafaros begins subject enrolment in Phase II trial of AZ-3102
Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance ...
Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustatin GM2 and NPC ...
Azafaros: €132 Million Secured To Develop Treatments For Lysosomal ...
#worldsymposia #world2025 #biotech #community #collaboration #awareness ...
#curegm1foundation #gm1gangliosidosis #curegm1foundation #azafaros # ...
I am proud that AZ-3102 was granted #orphandrug designation in #GM2 ...
Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and ...
Azafaros' Drug For Inherited Metabolic Diseases Funded with €25M
Azafaros: ODD for AZ-3102 to Treat GM2 Gangliosidosis
#rainbow #pronto #worldsymposia #world2025 #biotech #community ...
#ceo #biotech #pharmaceutical #orphanmedicines #rarediseases # ...
#collaboration #rarediseases #teamwork #lysosomalstoragedisorders #gm1 ...
Azafaros' €132M series B will fund brain-penetrant drug trials
#forbion #azafaros #lifesciences #raredisease #venturecapital #biotech ...
Des données positives sur la maladie de Niemann-Pick de type C (NPC) et ...
EUCOPE - European Confederation of Pharmaceutical Entrepreneurs on ...
#worldorphandrugcongress #patientadvocates #worldorphandrugcongress # ...
#clinical #smallmolecule #rare #neurogenetic #investor #disease # ...
1.46亿美元B轮融资，进军三种罕见代谢病三期临床
#gm1 #gm2 #gm1 #gm2 #npc #sfnp2024 #biotech #rarediseases #innovation # ...
#rarediseaseday2024 #shareyourcolours #rarediseaseday2024 # ...
#niemannpickawarenessmonth #rarediseases #collaboration #awareness #npc ...
.jpg)
)
.jpg)
